Champions Oncology (Champions), a developer of advanced technology solutions and services to personalize the development and use of oncology drugs, has signed a new discovery and drug development partnership with Teva Pharmaceutical Industries (TEVA).
Under the deal, Champions TumorGraft technology platform will be used to improve and speed up the clinical development of many oncology compounds of Teva.
The partnership is aimed at identifying highly responsive cancer subtypes, and their corresponding molecular and biochemical biomarkers of responsiveness to Teva's novel therapeutic agents, which would lead to new therapeutic options for patients with cancer.
The deal will also see Teva pay an upfront fee to Champions, which may also receive milestone payments and royalties for the compounds being studied if the response hypotheses are used for clinical trial design and resulting commercial success of the compounds.
Development process of the oncology compounds will comprise initial screening studies on large numbers of TumorGraft models to develop response hypotheses for different tumor types and sub-populations.